ADHD Stimulant APIs
Attention Deficit Hyperactivity Disorder
CommercialActive
Key Facts
About Noramco
Noramco is a globally integrated leader in the development and manufacture of controlled substance APIs, serving pharmaceutical companies in the ADHD, pain management, and addiction treatment markets. Its key strategic advantages include backward integration through its sister company Tasmanian Alkaloids, providing secure access to premium narcotic raw materials, and extensive DEA-compliant manufacturing capacity in the US and Europe. The company has recently formed the Noramco Group with Purisys and Halo Pharma to offer integrated API and drug product supply chain services, positioning itself as a critical, onshore supplier in a geopolitically sensitive sector.
View full company profileTherapeutic Areas
Other Attention Deficit Hyperactivity Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| ADHD Biomarker Program | Linus Biotechnology | Pre-clinical |
| ADHD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| ADHD Drug (unspecified) | Granules India | ANDA Tentative Approval |